Last €2.31 EUR
Change Today 0.00 / 0.00%
Volume 0.0
O5O On Other Exchanges
Symbol
Exchange
Helsinki
Helsinki
OTC US
OTC US
As of 9:42 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

oriola-kd oyj b shares (O5O) Snapshot

Open
€2.29
Previous Close
€2.31
Day High
€2.32
Day Low
€2.29
52 Week High
01/16/14 - €2.78
52 Week Low
08/30/13 - €2.17
Market Cap
348.4M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
104.1M
EX-Date
03/25/14
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORIOLA-KD OYJ   B SHARES (O5O)

Related News

No related news articles were found.

oriola-kd oyj b shares (O5O) Related Businessweek News

No Related Businessweek News Found

oriola-kd oyj b shares (O5O) Details

Oriola-KD Corporation operates as a pharmaceutical retail and wholesale company in Northern Europe and Russia. The company operates in Pharmaceutical Trade Finland and Baltics, Pharmaceutical Trade Sweden, and Pharmaceutical Trade Russia segments. It distributes various pharmaceuticals; and provides various added value services for pharmaceutical manufacturers and pharmacies, such as distribution of clinical trials medicines and medical samples, as well as storage and distribution services for marketing materials, and other logistics solutions. The company also sells and markets consumer health products that comprise vitamins, food supplements, pharmacy cosmetics, skincare products, tests, sports drinks, and wound care products to pharmacies and the groceries. It has 290 pharmacies in Sweden; and 239 pharmacies located in Moscow. The company is headquartered in Espoo, Finland.

4,899 Employees
Last Reported Date: 07/24/14

oriola-kd oyj b shares (O5O) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: €569.7K
Compensation as of Fiscal Year 2013.

oriola-kd oyj b shares (O5O) Key Developments

Oriola-KD Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reports Impairment Charges for the Second Quarter Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Oriola-KD Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's net sales were EUR 593.1 million, compared to EUR 652.1 million for the last year. Operating loss was EUR 71.2 million, compared to EUR 0.3 million for the last year. Loss before taxes was EUR 73.9 million, compared to EUR 4.0 million for the last year. Attribution of loss for the period to parent company shareholders was EUR 82.1 million or EUR 0.55 per diluted share, compared to EUR 2.8 million or EUR 0.02 per diluted share for the last year. Adjusted loss for the period was EUR 82.6 million, compared to EUR 2.8 million for the last year. EBITDA was EUR 6.6 million compared to EUR 5.2 million for the last year. Net cash inflow from operations was EUR 17.1 million compared to EUR 24.6 million for the last year. For the six months, the company's net sales were EUR 1,186.9 million, compared to EUR 1,264.5 million for the last year. Operating loss was EUR 64.1 million, compared to EUR 2.0 million for the last year. Loss before taxes was EUR 70.5 million, compared to EUR 3.0 million for the last year. Attribution of loss for the period to parent company shareholders was EUR 79.5 million or EUR 0.53 per diluted share, compared to EUR 2.1 million or EUR 0.01 per diluted share for the last year. Adjusted loss for the period was EUR 80.3 million, compared to EUR 2.1 million for the last year. Net cash outflow from operating activities was EUR 8.7 million, compared to EUR 1.5 million for the last year. EBITDA was EUR 20.2 million, compared to EUR 12.7 million for the last year. Negative return on equity was 53.0%, compared to 1.4% for the last year. Net interest-bearing debt was EUR 166.1 million as on June 30, 2014 compared to EUR 199.8 million as on June 30, 2013. For the year 2014, the company estimated that operating profit excluding non-recurring items will increase compared to 2013 actual. Net sales are estimated to decrease from 2013 level. The second quarter results include EUR 77.2 million impairment charge for Russian pharmaceutical wholesale business. The impairment charge consists of goodwill EUR 70.2 million, intangible assets EUR 0.9 million and deferred tax assets EUR 6.1 million relating to the Russian wholesale operations subsidiary. The impairment charge is reported in the second quarter interim results as a non-recurring, non- cash item of expense.

Oriola-KD Revises Earnings Guidance for the Year 2014

Oriola-KD revised earnings guidance for the year 2014. For the year, the company estimates that operating profit excluding non-recurring items will increase compared to 2013 actual. Net sales is estimated to decrease from 2013 level. The company estimated before that net sales and operating profit excluding non-recurring items will increase compared to 2013 actual.

Oriola-KD Corporation, H1 2014 Earnings Call, Jul 24, 2014

Oriola-KD Corporation, H1 2014 Earnings Call, Jul 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
O5O:GR €2.31 EUR 0.00

O5O Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for O5O.
View Industry Companies
 

Industry Analysis

O5O

Industry Average

Valuation O5O Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORIOLA-KD OYJ B SHARES, please visit www.oriola-kd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.